Respiratory syncytial virus infections Trials in Chicago, United States
Conditions / Respiratory syncytial virus infections / Chicago, United States
Respiratory syncytial virus infections has been the subject of sustained clinical investigation across multiple research sites.
23 total trials for this combination
Showing top 10 of 23 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05238025 | MVA-BN-RSV Vaccine Trial | TERMINATED | PHASE3 |
| NCT00129766 | Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children | COMPLETED | PHASE3 |
| NCT01065935 | Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) | COMPLETED | PHASE2 |
| NCT03959488 | A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children | COMPLETED | PHASE2/PHASE3 |
| NCT03656510 | Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection | TERMINATED | PHASE2 |
| NCT04886596 | Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above | COMPLETED | PHASE3 |
| NCT00384462 | Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants | COMPLETED | — |
| NCT03979313 | A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY) | COMPLETED | PHASE3 |
| NCT02878330 | A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. | COMPLETED | PHASE2 |
| NCT06534892 | An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study | ACTIVE_NOT_RECRUITING | PHASE3 |